Partnerships for Outsourcing eBook
Read the article:
Read the eBook:
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
The global biopharma market has experienced a remarkable period of evolution and expansion. In that time, parenteral medications have become one of the industry’s most important innovation and growth drivers.
Fueled by a continuing shift toward at-home, self-administered care—an established trend accelerated by the COVID-19 pandemic—the rapid surge in demand for injectable therapies is set to continue in the coming years. Between 2020 and 2027, sales of parenteral medications are projected to expand from 53–57% of global market volume, with most of those gains taken away from oral drugs (1).
Read this article in BioPharm International's
Read the article:
Read the eBook:
Markus Hörburger is product and service manager Secondary Packaging & Device Assembly at Vetter.
BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 14–17
When referring to this article, please cite it as M. Hörburger, “Converting Injectable Therapies to Combination Drug-Device Products,” BioPharm International Partnerships for Outsourcing eBook (May 2022).
over 3 years ago
Balancing Internal Focus Against External Capabilitiesover 3 years ago
The Essential Ingredient in any Sponsor-CRO Partnership: Trustover 3 years ago
Fostering Orphan Drugsover 3 years ago
The CDMO Carouselover 3 years ago
What Outsourcing Partners Wish You KnewStay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.